Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide on Macrophage Polarization in Type 2 Diabetes
NCT02650206Phase 1Completed
- Sponsor
- Stanford University
- Start
- Jan 2015
- Primary completion
- Sep 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Stanford University. Primary endpoint: Percentage of M2 macrophages in adipose tissue and peripheral blood at 12 weeks. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02650206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650206.